Please check your internet connection and try again.
# Clobazam (Oral Formulation)
## Overview
Clobazam is a benzodiazepine derivative with anticonvulsant properties. It is a Schedule IV controlled substance.
## Primary Indications
* Adjunctive therapy for seizures associated with Lennox-Gastaut syndrome (LGS) in patients 2 years of age and older.
* Off-label use for other seizure types or epilepsy syndromes.
## Adult Dosing
* **Lennox-Gastaut Syndrome:** Initial dose: 5 mg twice daily. Increase by 5-10 mg every week as needed. Usual maintenance dose: 10-20 mg twice daily. Maximum recommended dose: 20 mg twice daily (40 mg total per day).
* **Other Indications (Off-label):** Dosing varies significantly based on indication and patient response. Titration is typically slow.
## Pediatric Dosing
* **Lennox-Gastaut Syndrome (2 years and older):**
* **2 to less than 10 years:** Initial dose: 5 mg once daily. Increase by 2.5-5 mg every week as needed. Usual maintenance dose: 5-10 mg twice daily. Maximum recommended dose: 10 mg twice daily (20 mg total per day).
* **10 years and older:** Initial dose: 5 mg twice daily. Increase by 5-10 mg every week as needed. Usual maintenance dose: 10 mg twice daily. Maximum recommended dose: 20 mg twice daily (40 mg total per day).
* **Less than 2 years:** Safety and efficacy not established. Use with caution and consider lower initial doses and slower titration due to potential for increased sensitivity.
## Dose Adjustments
* **Hepatic Impairment:** Use with caution. No specific dosing adjustments are established, but consider starting at the lower end of the dosing range and titrating slowly.
* **Renal Impairment:** Use with caution. No specific dosing adjustments are established, but consider starting at the lower end of the dosing range and titrating slowly.
## Contraindications
* Known hypersensitivity to clobazam or other benzodiazepines.
* Severe hepatic impairment.
## Adverse Effects
* **Common:** Somnolence, drooling, constipation, decreased appetite, fatigue, vomiting, respiratory infections, ataxia, aggression.
* **Serious:** Severe skin reactions (Stevens-Johnson syndrome, toxic epidermal necrolysis - particularly with co-administration of valproate), suicidal ideation or behavior, withdrawal symptoms (seizures, rebound insomnia, anxiety, tremors, muscle cramps, psychosis), respiratory depression (especially when used with other CNS depressants), paradoxical reactions (agitation, irritability, hallucinations).
## Key Drug Interactions
* **Central Nervous System (CNS) Depressants:** Increased risk of sedation, respiratory depression (e.g., alcohol, opioids, other benzodiazepines, barbiturates, sedating antihistamines).
* **CYP1A2 Substrates:** Clobazam is a weak inhibitor of CYP1A2. Caution may be warranted with concomitant use of narrow therapeutic index CYP1A2 substrates.
* **CYP2C19 Substrates:** Clobazam can inhibit CYP2C19. This may increase concentrations of drugs metabolized by CYP2C19 (e.g., phenytoin, proton pump inhibitors).
* **CYP3A4 Substrates:** Clobazam is metabolized by CYP3A4. Potent CYP3A4 inducers or inhibitors may affect clobazam levels.
* **Valproic Acid:** Increased valproic acid levels and increased risk of severe skin reactions have been reported. Close monitoring for skin reactions is crucial.
## Monitoring
* Seizure frequency and severity.
* Signs of CNS depression (somnolence, dizziness).
* Signs of withdrawal symptoms upon discontinuation.
* Suicidal ideation or behavior.
* Skin integrity, especially if co-administered with valproic acid.
* Therapeutic drug monitoring for clobazam and its active metabolite, N-desmethylclobazam, may be considered in specific situations, particularly if efficacy or toxicity is suspected.
## Clinical Pearls
* Clobazam is generally considered to have less sedative and motor impairment effects compared to some other benzodiazepines, but somnolence is still a common side effect.
* Dose should be individualized and titrated slowly to minimize adverse effects and maximize efficacy.
* Abrupt discontinuation can lead to severe withdrawal symptoms. Tapering of the dose is essential.
* Due to the risk of severe skin reactions, particularly with concurrent valproate use, patients and caregivers should be educated to report any rash immediately.
* Clobazam is hepatically metabolized; monitor liver function if concerns arise.
***
**Disclaimer:** This information is intended for healthcare professionals. Always consult the most current prescribing information and relevant literature for complete details and to ensure patient safety. Local protocols and guidelines may influence specific dosing and management.
